Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers

Yan Xu, Zhongzhou Shen, Donald W. Wiper, Minzhi Wu, Richard E. Morton, Paul Elson, Alexander W. Kennedy, Jerome Belinson, Maurie Markman, Graham Casey

Research output: Contribution to journalArticle

518 Citations (Scopus)

Abstract

Context. - Lysophosphatidic acid (LPA) has been shown to stimulate proliferation of ovarian cancer cells and is present in the ascitic fluid of patients with ovarian cancer. Objectives. - To determine whether elevated levels of LPA are present in plasma from patients with ovarian cancer and other gynecologic malignancies compared with healthy controls and to evaluate whether an elevated LPA plasma level may be a biomarker for these diseases. Design. - A research assay was used to measure total LPA levels in plasma from healthy women and women with different diseases. All LPA assays and comparison of LPA levels and CA125 (an ovarian cancer biomarker) levels were performed by observers blinded to patient status or group. Setting. - The Cleveland Clinic Foundation. Participants. - A convenience sample of 48 healthy control women, 48 women with ovarian cancer, 36 women with other gynecologic cancers, 17 women with benign gynecologic diseases, 11 women with breast cancer, and 5 women with leukemias. Main Outcome Measures. - Total LPA levels in plasma samples from patients and controls. Results. - Patients in the ovarian cancer group had significantly higher plasma LPA levels (mean, 8.6 μmol/L; range, 1.0-43.1 μmol/L) compared with the healthy control group (mean, 0.6 μmol/L; range,

Original languageEnglish (US)
Pages (from-to)719-723
Number of pages5
JournalJournal of the American Medical Association
Volume280
Issue number8
StatePublished - Aug 26 1998
Externally publishedYes

Fingerprint

Biomarkers
Ovarian Neoplasms
Neoplasms
Female Genital Diseases
lysophosphatidic acid
Ascitic Fluid
Tumor Biomarkers
Leukemia
Outcome Assessment (Health Care)
Breast Neoplasms
Control Groups
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Xu, Y., Shen, Z., Wiper, D. W., Wu, M., Morton, R. E., Elson, P., ... Casey, G. (1998). Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. Journal of the American Medical Association, 280(8), 719-723.

Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. / Xu, Yan; Shen, Zhongzhou; Wiper, Donald W.; Wu, Minzhi; Morton, Richard E.; Elson, Paul; Kennedy, Alexander W.; Belinson, Jerome; Markman, Maurie; Casey, Graham.

In: Journal of the American Medical Association, Vol. 280, No. 8, 26.08.1998, p. 719-723.

Research output: Contribution to journalArticle

Xu, Y, Shen, Z, Wiper, DW, Wu, M, Morton, RE, Elson, P, Kennedy, AW, Belinson, J, Markman, M & Casey, G 1998, 'Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers', Journal of the American Medical Association, vol. 280, no. 8, pp. 719-723.
Xu, Yan ; Shen, Zhongzhou ; Wiper, Donald W. ; Wu, Minzhi ; Morton, Richard E. ; Elson, Paul ; Kennedy, Alexander W. ; Belinson, Jerome ; Markman, Maurie ; Casey, Graham. / Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. In: Journal of the American Medical Association. 1998 ; Vol. 280, No. 8. pp. 719-723.
@article{0b0d70a93fa044c78859859f69e403f7,
title = "Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers",
abstract = "Context. - Lysophosphatidic acid (LPA) has been shown to stimulate proliferation of ovarian cancer cells and is present in the ascitic fluid of patients with ovarian cancer. Objectives. - To determine whether elevated levels of LPA are present in plasma from patients with ovarian cancer and other gynecologic malignancies compared with healthy controls and to evaluate whether an elevated LPA plasma level may be a biomarker for these diseases. Design. - A research assay was used to measure total LPA levels in plasma from healthy women and women with different diseases. All LPA assays and comparison of LPA levels and CA125 (an ovarian cancer biomarker) levels were performed by observers blinded to patient status or group. Setting. - The Cleveland Clinic Foundation. Participants. - A convenience sample of 48 healthy control women, 48 women with ovarian cancer, 36 women with other gynecologic cancers, 17 women with benign gynecologic diseases, 11 women with breast cancer, and 5 women with leukemias. Main Outcome Measures. - Total LPA levels in plasma samples from patients and controls. Results. - Patients in the ovarian cancer group had significantly higher plasma LPA levels (mean, 8.6 μmol/L; range, 1.0-43.1 μmol/L) compared with the healthy control group (mean, 0.6 μmol/L; range,",
author = "Yan Xu and Zhongzhou Shen and Wiper, {Donald W.} and Minzhi Wu and Morton, {Richard E.} and Paul Elson and Kennedy, {Alexander W.} and Jerome Belinson and Maurie Markman and Graham Casey",
year = "1998",
month = "8",
day = "26",
language = "English (US)",
volume = "280",
pages = "719--723",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers

AU - Xu, Yan

AU - Shen, Zhongzhou

AU - Wiper, Donald W.

AU - Wu, Minzhi

AU - Morton, Richard E.

AU - Elson, Paul

AU - Kennedy, Alexander W.

AU - Belinson, Jerome

AU - Markman, Maurie

AU - Casey, Graham

PY - 1998/8/26

Y1 - 1998/8/26

N2 - Context. - Lysophosphatidic acid (LPA) has been shown to stimulate proliferation of ovarian cancer cells and is present in the ascitic fluid of patients with ovarian cancer. Objectives. - To determine whether elevated levels of LPA are present in plasma from patients with ovarian cancer and other gynecologic malignancies compared with healthy controls and to evaluate whether an elevated LPA plasma level may be a biomarker for these diseases. Design. - A research assay was used to measure total LPA levels in plasma from healthy women and women with different diseases. All LPA assays and comparison of LPA levels and CA125 (an ovarian cancer biomarker) levels were performed by observers blinded to patient status or group. Setting. - The Cleveland Clinic Foundation. Participants. - A convenience sample of 48 healthy control women, 48 women with ovarian cancer, 36 women with other gynecologic cancers, 17 women with benign gynecologic diseases, 11 women with breast cancer, and 5 women with leukemias. Main Outcome Measures. - Total LPA levels in plasma samples from patients and controls. Results. - Patients in the ovarian cancer group had significantly higher plasma LPA levels (mean, 8.6 μmol/L; range, 1.0-43.1 μmol/L) compared with the healthy control group (mean, 0.6 μmol/L; range,

AB - Context. - Lysophosphatidic acid (LPA) has been shown to stimulate proliferation of ovarian cancer cells and is present in the ascitic fluid of patients with ovarian cancer. Objectives. - To determine whether elevated levels of LPA are present in plasma from patients with ovarian cancer and other gynecologic malignancies compared with healthy controls and to evaluate whether an elevated LPA plasma level may be a biomarker for these diseases. Design. - A research assay was used to measure total LPA levels in plasma from healthy women and women with different diseases. All LPA assays and comparison of LPA levels and CA125 (an ovarian cancer biomarker) levels were performed by observers blinded to patient status or group. Setting. - The Cleveland Clinic Foundation. Participants. - A convenience sample of 48 healthy control women, 48 women with ovarian cancer, 36 women with other gynecologic cancers, 17 women with benign gynecologic diseases, 11 women with breast cancer, and 5 women with leukemias. Main Outcome Measures. - Total LPA levels in plasma samples from patients and controls. Results. - Patients in the ovarian cancer group had significantly higher plasma LPA levels (mean, 8.6 μmol/L; range, 1.0-43.1 μmol/L) compared with the healthy control group (mean, 0.6 μmol/L; range,

UR - http://www.scopus.com/inward/record.url?scp=0032569235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032569235&partnerID=8YFLogxK

M3 - Article

C2 - 9728644

AN - SCOPUS:0032569235

VL - 280

SP - 719

EP - 723

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 8

ER -